Arriving in the arena of obesity treatment, retatrutide represents a different approach. Unlike many current medications, retatrutide works as a twin agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) receptors. This concurrent activation encourages various helpful effects, suc